Importantly, we demonstrate robust pre-clinical efficacy of α-LGR5 in all three therapeutic modalities in a murine model of human pre-B-ALL thus supporting continued development of α-LGR5-based immune therapies for all LGR5-expressing cancer types. This evidence concerns the gene LGR5 and cancer.